High prevalence of human papillomavirus type 16 (HPV-16) in breast cancer with chrysotile asbestos in more than 90% of over 500 mammograms of human breast cancer indicated potential involvement of HPV-16 in other cancers and found them in adenocarcinoma of the esophagus, stomach, colon & prostate gland but not in the pancreas: future treatment & prevention of HPV-16 infected cancers should include safe effective treatment or prevention of HPV-16 & asbestos with average vitamin D3 400 I.U.

Yoshiaki Omura
New York Medical College, USA

Our latest study with over 500 cases of published breast cancer mammogram analysis indicated in more than 90% Human Breast Cancers had HPV-16 & Chrysotile Asbestos with a relatively smooth outline. Less than 5% had HPV-18 & Tremolite Asbestos, in which the outline of tumor was sawtooth-like, zigzag and irregular. Because of this high incident of involvement of HPV-16 in breast cancer, the author investigated which cancers of other organs may have HPV-16 infection with Chrysotile asbestos. The following cancer tissues were found to have HPV-16 infection with Chrysotile Asbestos: 1) Adenocarcinoma of tongue; 2) Adenocarcinoma of Esophagus (Squamous Cell Carcinoma did not have any one of HPV-16, -18, & -33); 3) Adenocarcinoma of Lung (Small Cell Carcinoma, Squamous Cell Carcinoma, and Large Cell Carcinoma did not have HPV-16, -18 & -33); 4) Adenocarcinoma of Stomach (but Scirrhous Carcinoma of Stomach and Signet Ring Cell Carcinoma of Stomach did not have HPV-16, -18 & -33); 5) Adenocarcinoma of Colon & Adenocarcinoma of Prostate Gland, but Adenocarcinoma of Pancreas did not have HPV-16, -18 or -33, but had Coxsackie Virus B. HPV-18 or HPV-33 were not found in other types of cancers of the same organs but all kinds of cancer examined had Chrysotile Asbestos with less than 5% of Breast Cancers. Thus safe & effective treatment or prevention of these cancers should also control HPV-16 & Asbestos along with a few beneficial optimal doses of mutually compatible supplements including Vitamin D3, average 400 I.U. for average adult cancer patients.

Biography

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed a non-invasive, quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

icaelt@yahoo.com